XMT-1522

News alerts, weekly reports and conference planners

Company:

Mersana

Drug class:

Microtubule inhibitor, HER2-targeted antibody-drug conjugate

HER-2 expression	Non Small Cell Lung Cancer	HER-2 expression	Non Small Cell Lung Cancer	XMT-1522 Sensitive: C3 – Early Trials XMT-1522 Sensitive : C3	XMT-1522 Sensitive: C3 – Early Trials XMT-1522 Sensitive : C3
HER-2 expression	Breast Cancer	HER-2 expression	Breast Cancer	XMT-1522 Sensitive: C3 – Early Trials XMT-1522 Sensitive : C3	XMT-1522 Sensitive: C3 – Early Trials XMT-1522 Sensitive : C3
HER-2 expression	Gastric Cancer	HER-2 expression	Gastric Cancer	XMT-1522 Sensitive: C3 – Early Trials XMT-1522 Sensitive : C3	XMT-1522 Sensitive: C3 – Early Trials XMT-1522 Sensitive : C3

Associations
(3)